BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20082263)

  • 1. Combined detection of p53, p16, Rb, and EGFR mutations in lung cancer by suspension microarray.
    Ye Y; Wang D; Su C; Rong T; Guo A
    Genet Mol Res; 2009 Dec; 8(4):1509-18. PubMed ID: 20082263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection of multiple gene mutations in non-small-cell lung cancer by suspension microarray].
    Wang D; Ye YK; Su CQ; Rong TH; Guo AY; Yi JH; Liu YJ
    Zhonghua Yi Xue Za Zhi; 2009 Dec; 89(48):3393-6. PubMed ID: 20223111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
    Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
    Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
    Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
    Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.
    Sanchez-Cespedes M; Reed AL; Buta M; Wu L; Westra WH; Herman JG; Yang SC; Jen J; Sidransky D
    Oncogene; 1999 Oct; 18(43):5843-9. PubMed ID: 10557071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
    Modi S; Kubo A; Oie H; Coxon AB; Rehmatulla A; Kaye FJ
    Oncogene; 2000 Sep; 19(40):4632-9. PubMed ID: 11030152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
    Chiba I; Takahashi T; Nau MM; D'Amico D; Curiel DT; Mitsudomi T; Buchhagen DL; Carbone D; Piantadosi S; Koga H
    Oncogene; 1990 Oct; 5(10):1603-10. PubMed ID: 1979160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relations of tumor suppressor gene p16 and RB to early diagnosis of lung cancer.
    Ye Y; Su C; Wang D; Guo W; Cheng X; Liu S; Liu Y; Liu B; Cao X; Shan X; Wu M
    Zhonghua Wai Ke Za Zhi; 2000 Dec; 38(12):885-9. PubMed ID: 11832187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers.
    Geradts J; Fong KM; Zimmerman PV; Maynard R; Minna JD
    Clin Cancer Res; 1999 Apr; 5(4):791-800. PubMed ID: 10213214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer.
    Fukui T; Ohe Y; Tsuta K; Furuta K; Sakamoto H; Takano T; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Asamura H; Tsuchida T; Kaneko M; Kusumoto M; Yamamoto S; Yoshida T; Tamura T
    Clin Cancer Res; 2008 Aug; 14(15):4751-7. PubMed ID: 18676744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression.
    Na II; Rho JK; Choi YJ; Kim CH; Park JH; Koh JS; Ryoo BY; Yang SH; Lee JC
    Lung Cancer; 2007 Jul; 57(1):96-102. PubMed ID: 17337084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development and application of the method for controlling contamination of tumor samples with normal cells to detect deletion of P16 gene in primary lung carcinoma].
    Ran R; Cao XA; Tian Y
    Zhonghua Jie He He Hu Xi Za Zhi; 1997 Jun; 20(3):136-40. PubMed ID: 10072815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
    Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
    Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.
    Yung TK; Chan KC; Mok TS; Tong J; To KF; Lo YM
    Clin Cancer Res; 2009 Mar; 15(6):2076-84. PubMed ID: 19276259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The expression of P16 and Rb proteins in 106 cases of lung cancer].
    Qin J; Chen G; Wang X
    Zhonghua Jie He He Hu Xi Za Zhi; 2000 Oct; 23(10):588-90. PubMed ID: 11372380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma.
    Iwakawa R; Kohno T; Anami Y; Noguchi M; Suzuki K; Matsuno Y; Mishima K; Nishikawa R; Tashiro F; Yokota J
    Clin Cancer Res; 2008 Jun; 14(12):3746-53. PubMed ID: 18559592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.
    Amann J; Kalyankrishna S; Massion PP; Ohm JE; Girard L; Shigematsu H; Peyton M; Juroske D; Huang Y; Stuart Salmon J; Kim YH; Pollack JR; Yanagisawa K; Gazdar A; Minna JD; Kurie JM; Carbone DP
    Cancer Res; 2005 Jan; 65(1):226-35. PubMed ID: 15665299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.